Peptide Comparison

Compare peptides side-by-side.

Pick up to four peptides and compare mechanism, evidence grade, pharmacokinetics, administration and risk profile in a single view.

Selection · 3 / 4

Save & share

Save a set to reload it later on this device, or copy a share link to send the exact comparison to someone else.

Export comparison

Download the full side-by-side table as a landscape PDF for reading, or a CSV for spreadsheets and further analysis.

AI comparison summary

Biggest differences across SS-31 (Elamipretide) · MOTS-c · Retatrutide

Focused on evidence grade, pharmacokinetics, and risks/interactions — with inline citations to the primary references on each peptide page.

Click Generate summary to have AI highlight the biggest differences between the peptides you've selected.

SS-31 (Elamipretide)

Grade BMitochondrial

Overview

Evidence grade: Grade B
Category: Mitochondrial
Primary focus: Mitochondrial membrane stabilization
Summary: Investigated for primary mitochondrial myopathies, heart failure, and age-related muscle dysfunction. Multiple Phase 2/3 human trials completed with mixed but mechanistically promising results.

Mechanism

Mechanism of action: Cell-permeable tetrapeptide that selectively binds cardiolipin on the inner mitochondrial membrane, preserving cristae architecture, improving electron transport chain efficiency, and reducing reactive oxygen species generation.
Evidence explainer: Grade B — supported by preclinical evidence plus at least one small human trial, pharmacokinetic study, or strong translational rationale. Human long-term safety is incomplete.

Pharmacokinetics

Route: Subcutaneous injection
Half-life: ~2.5 hours
PK notes: SS-31 (Elamipretide) is administered subcutaneous injection with an approximate systemic half-life of ~2.5 hours. Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (Daily) is designed to match receptor kinetics rather than plasma exposure. Cell-permeable tetrapeptide that selectively binds cardiolipin on the inner mitochondrial membrane, preserving cristae architecture, improving electron transport chain efficiency, and reducing reactive oxygen species generation.

Administration

Typical dose: 40 mg
Frequency: Daily
Cycle length: Cyclical, physician-supervised
Timing: Morning
Protocol steps: Route: Subcutaneous injection. Typical starting dose 40 mg, Daily.
Timing: Morning — keep it the same each dosing day to make effects legible.
Cycle length: Cyclical, physician-supervised. Reassess with bloods and symptom logs before repeating.
Rotate sites across the abdomen (avoiding a 2 cm radius around the navel), outer thighs and flanks. Never inject through a bruise or mole.

Benefits

Reported benefits: Restored mitochondrial ATP production in preclinical models
Improved 6-minute walk distance in mitochondrial myopathy trials
Reduced oxidative stress markers
Common stacks: CoQ10, Urolithin A, NMN

Risks

Side effects: Injection site reactions
Headache
Long-term safety still under study
Contraindications: Pregnancy
Active malignancy (theoretical)
Interactions: Antioxidant therapies — Mechanistic overlap; effect unclear.
Legal status: Investigational. Not FDA-approved; available only via clinical trials or as a research chemical.

MOTS-c

Grade BMitochondrial

Overview

Evidence grade: Grade B
Category: Mitochondrial
Primary focus: Mitochondrial signaling
Summary: Promising mitokine with metabolic and exercise-mimetic effects in rodents. Early human pharmacokinetic data is emerging.

Mechanism

Mechanism of action: Mitochondrial-derived peptide encoded within the 12S rRNA. Activates AMPK, improves insulin sensitivity, and regulates nuclear gene expression in response to metabolic stress.
Evidence explainer: Grade B — supported by preclinical evidence plus at least one small human trial, pharmacokinetic study, or strong translational rationale. Human long-term safety is incomplete.

Pharmacokinetics

Route: Subcutaneous
Half-life: ~2 hours
PK notes: MOTS-c is administered subcutaneous with an approximate systemic half-life of ~2 hours. Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (2–3× weekly) is designed to match receptor kinetics rather than plasma exposure. Mitochondrial-derived peptide encoded within the 12S rRNA. Activates AMPK, improves insulin sensitivity, and regulates nuclear gene expression in response to metabolic stress.

Administration

Typical dose: 5–10 mg
Frequency: 2–3× weekly
Cycle length: 8–12 weeks
Timing: Pre-training mornings
Protocol steps: Route: Subcutaneous. Typical starting dose 5–10 mg, 2–3× weekly.
Timing: Pre-training mornings — keep it the same each dosing day to make effects legible.
Cycle length: 8–12 weeks. Reassess with bloods and symptom logs before repeating.
Rotate sites across the abdomen (avoiding a 2 cm radius around the navel), outer thighs and flanks. Never inject through a bruise or mole.

Benefits

Reported benefits: Improved glucose disposal in preclinical models
Enhanced exercise capacity
Mitochondrial biogenesis signaling
Common stacks: NMN, Urolithin A, Zone 2 training

Risks

Side effects: Mild flushing
Transient fatigue
Injection site reaction
Contraindications: Active malignancy
Pregnancy
Interactions: Metformin — Both activate AMPK — stacking effect unclear.
SGLT2 inhibitors — Potential additive glucose-lowering.
Legal status: Research chemical. Not approved for therapeutic use in humans.

Retatrutide

Grade AMetabolic

Overview

Evidence grade: Grade A
Category: Metabolic
Primary focus: Triple GIP/GLP-1/glucagon agonist
Summary: Phase II trial results showed ~24% mean weight loss at 48 weeks at the 12 mg dose — markedly exceeding tirzepatide and prior GLP-1 monotherapies. Currently in Phase III; not yet FDA-approved but expected to be a landmark obesity and metabolic therapy.

Mechanism

Mechanism of action: First-in-class triple agonist of GIP, GLP-1, and glucagon receptors. The GLP-1 and GIP arms drive glucose-dependent insulin secretion and satiety; the glucagon arm increases energy expenditure — producing the largest weight-loss effect of any incretin to date.
Evidence explainer: Grade A — supported by multiple randomised human trials or an approved regulatory indication. Mechanism, dosing and safety are well characterised in humans.

Pharmacokinetics

Route: Subcutaneous injection
Half-life: ~6 days (supports once-weekly dosing)
PK notes: Retatrutide is administered subcutaneous injection with an approximate systemic half-life of ~6 days (supports once-weekly dosing). Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (Once weekly) is designed to match receptor kinetics rather than plasma exposure. First-in-class triple agonist of GIP, GLP-1, and glucagon receptors. The GLP-1 and GIP arms drive glucose-dependent insulin secretion and satiety; the glucagon arm increases energy expenditure — producing the largest weight-loss effect of any incretin to date.

Administration

Typical dose: Titrated 2 mg → 4 mg → 8 mg → 12 mg
Frequency: Once weekly
Cycle length: Ongoing; weight regain occurs on cessation
Timing: Same day each week; any time of day
Protocol steps: Route: Subcutaneous injection. Typical starting dose Titrated 2 mg → 4 mg → 8 mg → 12 mg, Once weekly.
Timing: Same day each week; any time of day — keep it the same each dosing day to make effects legible.
Cycle length: Ongoing; weight regain occurs on cessation. Reassess with bloods and symptom logs before repeating.
Rotate sites across the abdomen (avoiding a 2 cm radius around the navel), outer thighs and flanks. Never inject through a bruise or mole.

Benefits

Reported benefits: ~24% mean weight loss at 48 weeks (Phase II)
Marked improvements in HbA1c, blood pressure, ApoB and liver fat
Convenient once-weekly dosing
Likely best-in-class cardiometabolic profile
Common stacks: Creatine monohydrate, Whey protein, Vitamin D3 + K2

Risks

Side effects: Nausea, vomiting, diarrhea (especially during titration)
Injection site reactions
Reduced appetite to the point of inadequate protein intake — pair with resistance training and protein targeting
Theoretical pancreatitis and gallbladder risk (class effect)
Contraindications: Personal or family history of medullary thyroid carcinoma
Multiple Endocrine Neoplasia type 2
Pregnancy and lactation
Prior severe reaction to GLP-1 agonists
Interactions: Insulin and sulfonylureas — Risk of hypoglycemia — dose reduction usually required.
Oral medications — Delayed gastric emptying may alter absorption; separate timing for narrow-therapeutic-index drugs.
Legal status: Investigational; not yet FDA-approved. Currently available only via clinical trials.

Attribute	SS-31 (Elamipretide) Grade BMitochondrial	MOTS-c Grade BMitochondrial	Retatrutide Grade AMetabolic
Overview
Evidence grade	Grade B	Grade B	Grade A
Category	Mitochondrial	Mitochondrial	Metabolic
Primary focus	Mitochondrial membrane stabilization	Mitochondrial signaling	Triple GIP/GLP-1/glucagon agonist
Summary	Investigated for primary mitochondrial myopathies, heart failure, and age-related muscle dysfunction. Multiple Phase 2/3 human trials completed with mixed but mechanistically promising results.	Promising mitokine with metabolic and exercise-mimetic effects in rodents. Early human pharmacokinetic data is emerging.	Phase II trial results showed ~24% mean weight loss at 48 weeks at the 12 mg dose — markedly exceeding tirzepatide and prior GLP-1 monotherapies. Currently in Phase III; not yet FDA-approved but expected to be a landmark obesity and metabolic therapy.
Mechanism
Mechanism of action	Cell-permeable tetrapeptide that selectively binds cardiolipin on the inner mitochondrial membrane, preserving cristae architecture, improving electron transport chain efficiency, and reducing reactive oxygen species generation.	Mitochondrial-derived peptide encoded within the 12S rRNA. Activates AMPK, improves insulin sensitivity, and regulates nuclear gene expression in response to metabolic stress.	First-in-class triple agonist of GIP, GLP-1, and glucagon receptors. The GLP-1 and GIP arms drive glucose-dependent insulin secretion and satiety; the glucagon arm increases energy expenditure — producing the largest weight-loss effect of any incretin to date.
Evidence explainer	Grade B — supported by preclinical evidence plus at least one small human trial, pharmacokinetic study, or strong translational rationale. Human long-term safety is incomplete.	Grade B — supported by preclinical evidence plus at least one small human trial, pharmacokinetic study, or strong translational rationale. Human long-term safety is incomplete.	Grade A — supported by multiple randomised human trials or an approved regulatory indication. Mechanism, dosing and safety are well characterised in humans.
Pharmacokinetics
Route	Subcutaneous injection	Subcutaneous	Subcutaneous injection
Half-life	~2.5 hours	~2 hours	~6 days (supports once-weekly dosing)
PK notes	SS-31 (Elamipretide) is administered subcutaneous injection with an approximate systemic half-life of ~2.5 hours. Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (Daily) is designed to match receptor kinetics rather than plasma exposure. Cell-permeable tetrapeptide that selectively binds cardiolipin on the inner mitochondrial membrane, preserving cristae architecture, improving electron transport chain efficiency, and reducing reactive oxygen species generation.	MOTS-c is administered subcutaneous with an approximate systemic half-life of ~2 hours. Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (2–3× weekly) is designed to match receptor kinetics rather than plasma exposure. Mitochondrial-derived peptide encoded within the 12S rRNA. Activates AMPK, improves insulin sensitivity, and regulates nuclear gene expression in response to metabolic stress.	Retatrutide is administered subcutaneous injection with an approximate systemic half-life of ~6 days (supports once-weekly dosing). Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (Once weekly) is designed to match receptor kinetics rather than plasma exposure. First-in-class triple agonist of GIP, GLP-1, and glucagon receptors. The GLP-1 and GIP arms drive glucose-dependent insulin secretion and satiety; the glucagon arm increases energy expenditure — producing the largest weight-loss effect of any incretin to date.
Administration
Typical dose	40 mg	5–10 mg	Titrated 2 mg → 4 mg → 8 mg → 12 mg
Frequency	Daily	2–3× weekly	Once weekly
Cycle length	Cyclical, physician-supervised	8–12 weeks	Ongoing; weight regain occurs on cessation
Timing	Morning	Pre-training mornings	Same day each week; any time of day
Protocol steps	Route: Subcutaneous injection. Typical starting dose 40 mg, Daily. Timing: Morning — keep it the same each dosing day to make effects legible. Cycle length: Cyclical, physician-supervised. Reassess with bloods and symptom logs before repeating. Rotate sites across the abdomen (avoiding a 2 cm radius around the navel), outer thighs and flanks. Never inject through a bruise or mole.	Route: Subcutaneous. Typical starting dose 5–10 mg, 2–3× weekly. Timing: Pre-training mornings — keep it the same each dosing day to make effects legible. Cycle length: 8–12 weeks. Reassess with bloods and symptom logs before repeating. Rotate sites across the abdomen (avoiding a 2 cm radius around the navel), outer thighs and flanks. Never inject through a bruise or mole.	Route: Subcutaneous injection. Typical starting dose Titrated 2 mg → 4 mg → 8 mg → 12 mg, Once weekly. Timing: Same day each week; any time of day — keep it the same each dosing day to make effects legible. Cycle length: Ongoing; weight regain occurs on cessation. Reassess with bloods and symptom logs before repeating. Rotate sites across the abdomen (avoiding a 2 cm radius around the navel), outer thighs and flanks. Never inject through a bruise or mole.
Benefits
Reported benefits	Restored mitochondrial ATP production in preclinical models Improved 6-minute walk distance in mitochondrial myopathy trials Reduced oxidative stress markers	Improved glucose disposal in preclinical models Enhanced exercise capacity Mitochondrial biogenesis signaling	~24% mean weight loss at 48 weeks (Phase II) Marked improvements in HbA1c, blood pressure, ApoB and liver fat Convenient once-weekly dosing Likely best-in-class cardiometabolic profile
Common stacks	CoQ10, Urolithin A, NMN	NMN, Urolithin A, Zone 2 training	Creatine monohydrate, Whey protein, Vitamin D3 + K2
Risks
Side effects	Injection site reactions Headache Long-term safety still under study	Mild flushing Transient fatigue Injection site reaction	Nausea, vomiting, diarrhea (especially during titration) Injection site reactions Reduced appetite to the point of inadequate protein intake — pair with resistance training and protein targeting Theoretical pancreatitis and gallbladder risk (class effect)
Contraindications	Pregnancy Active malignancy (theoretical)	Active malignancy Pregnancy	Personal or family history of medullary thyroid carcinoma Multiple Endocrine Neoplasia type 2 Pregnancy and lactation Prior severe reaction to GLP-1 agonists
Interactions	Antioxidant therapies — Mechanistic overlap; effect unclear.	Metformin — Both activate AMPK — stacking effect unclear. SGLT2 inhibitors — Potential additive glucose-lowering.	Insulin and sulfonylureas — Risk of hypoglycemia — dose reduction usually required. Oral medications — Delayed gastric emptying may alter absorption; separate timing for narrow-therapeutic-index drugs.
Legal status	Investigational. Not FDA-approved; available only via clinical trials or as a research chemical.	Research chemical. Not approved for therapeutic use in humans.	Investigational; not yet FDA-approved. Currently available only via clinical trials.

← Back to all peptides